Skip to main content
TipRanks
Go Ultimate75% OFF

Co-Diagnostics (CODX) AI Stock Analysis

1,692 Followers
CODX

Co-Diagnostics

(NASDAQ:CODX)

Select Model
Rating:40Underperform
Price Target:$0.27â–²(6.20% Upside)
Action:reiterated
Date:11/11/26

CODX scores low primarily due to severely weakened financial performance (minimal revenue, large losses, and heavy cash burn with a shrinking capital base) and very bearish technicals (price far below major moving averages with negative momentum). Operational progress discussed on the earnings call provides some upside optionality, but near-term liquidity needs and potentially dilutive financing/govemance frictions keep overall risk elevated.

Positive Factors
Regulatory and clinical progressThe completed analytical and clinical work, together with the dual FDA submission, advances Co-Diagnostics toward potential commercialization of its multiplex respiratory assay. Regulatory progress can reduce development uncertainty and create a foundation for broader adoption if authorization and market execution follow.
Negative Factors
Minimal revenue and severe lossesThe collapse in revenue leaves the business far below the scale needed to support its diagnostic development infrastructure. Negative gross profit and exceptionally deep net losses indicate that current sales do not cover direct costs or operating expenses, making successful commercialization or major cost reduction essential.

Co-Diagnostics (CODX) vs. SPDR S&P 500 ETF (SPY)

-100%-75%-50%-25%0%25%CODX-97.60%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$1.93M
Dividend Yield
―
Average Volume (3M)
1.98M
Price to Earnings (P/E)
-0.0
Beta (1Y)
3.00
Revenue Growth
28.89%
EPS Growth
34.53%
Country
US
Employees
115
Sector
General
Sector Strength
55
Industry
Biotechnology

Co-Diagnostics Business Overview & Revenue Model

Company Description

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internat...

Co-Diagnostics Earnings Call Summary

Earnings Call Date:Aug 13, 2026(Q2-2026)|% Change Since:-82.68%|Next Earnings Date:May 15, 2019
Earnings Call SentimentNeutral

The call conveyed meaningful operational and regulatory progress — including a dual FDA submission for an upper respiratory multiplex assay, >1,400-patient clinical enrollment, >10,000 analytical PCR runs, TB program advancement toward ERPD, a blood-based Ebola proof-of-concept, strengthened international manufacturing partnerships, and reduced operating expenses that improved net loss and adjusted EBITDA. However, these positives are counterbalanced by a very low revenue base ($166K), a steep decline in cash to $3.6M (≈70% drop), continued operating losses, and materially reduced total assets. While execution milestones materially de-risk the technology and regulatory path, the company faces near-term liquidity and commercialization scaling risks.

Positive Updates

Regulatory Submission — Dual 510(k) and CLIA-waived for Flu A/B & RSV
Submitted a dual 510(k) and CLIA-waived application to FDA for the Flu A/B and RSV assay on the Co-Dx PCR platform; follows completion of analytical and clinical performance studies (27 analytical studies, >10,000 PCR runs) and a clinical study enrolling >1,400 symptomatic patients across 9 U.S. sites.

Negative Updates

Very Low Revenue Base
Total revenue for Q2 2026 was only $166K, up modestly from $163K year-over-year (≈+1.8%), indicating commercialization has not yet generated meaningful recurring sales.

Company Guidance

Management's guidance emphasized continued near‑term operating losses while advancing toward commercialization and prioritizing regulatory, clinical, commercial and platform milestones; Q2 FY2026 results included revenue of $166k (vs. $163k), cost of revenue $45k, gross profit ≈$121k (vs. $131k), operating expenses $6.3M (vs. $8.2M), R&D $4.2M (vs. $4.7M), sales & marketing $467k (vs. $610k), G&A $1.5M (vs. $2.6M), net loss $6.3M or $1.46 per share (vs. $7.7M or $7.00), adjusted EBITDA loss $5.8M (vs. $7.2M), cash $3.6M (vs. $11.9M at 2025 year‑end), total assets $16.6M and liabilities $3.9M; operational metrics and milestones include 27 analytical studies and >10,000 upper‑respiratory PCR runs, enrollment of >1,400 symptomatic patients across 9 U.S. sites, submission of a dual 510(k)/CLIA‑waived Flu A/B+RSV application, planned TB submissions to India’s CDSCO and WHO ERPD later this year, a C‑CAMP request for 200 Bundibugyo tests, cloud expansion to India and Saudi Arabia, and ongoing evaluation of equity, debt, strategic transactions and nondilutive funding to support these objectives.

Co-Diagnostics Financial Statement Overview

Summary

Overall fundamentals are very weak: revenue has collapsed from 2021 and remains minimal, profitability is deeply negative (including negative TTM gross profit), and cash flow shows persistent, material operating and free-cash-flow burn. A modest positive is low leverage, but the equity and asset base has eroded sharply, increasing financing and execution risk.

Income Statement

14Very Negative

Balance Sheet

45Neutral

Cash Flow

12Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue858.89K622.49K3.92M6.81M34.22M97.89M
Gross Profit-81.37K400.11K2.92M2.63M28.74M86.31M
EBITDA-46.84M-47.41M-36.20M-36.88M-10.31M45.97M
Net Income-47.48M-46.90M-37.64M-35.33M-14.24M36.66M
Balance Sheet
Total Assets12.79M24.74M64.00M95.32M123.09M160.03M
Cash, Cash Equivalents and Short-Term Investments714.80K11.88M29.75M58.55M81.26M89.86M
Total Debt1.56M1.24M2.15M2.99M347.92K0
Total Liabilities3.37M4.11M9.69M9.31M8.57M25.56M
Stockholders Equity9.43M20.63M54.31M86.01M114.52M134.48M
Cash Flow
Free Cash Flow-27.19M-29.84M-29.90M-23.45M5.14M40.41M
Operating Cash Flow-26.88M-29.14M-29.16M-22.08M6.57M41.08M
Investing Cash Flow-654.72K26.27M17.07M15.39M-58.17M4.10M
Financing Cash Flow16.81M11.81M103.91K-1.36M-14.03M450.40K

Co-Diagnostics Technical Analysis

Technical Analysis SentimentNegative
Last Price0.26

Price Trends

50DMA0.80Negative
100DMA1.35Negative
200DMA2.07Negative

Market Momentum

MACD-0.17Negative
RSI23.80Positive
STOCH15.42Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CODX, the sentiment is Negative. The current price of 0.26 is below the 20-day moving average (MA) of 0.42, below the 50-day MA of 0.80, and below the 200-day MA of 2.07, indicating a bearish trend. The MACD of -0.17 indicates Negative momentum. The RSI at 23.80 is Positive, neither overbought nor oversold. The STOCH value of 15.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CODX.

Co-Diagnostics Risk Analysis

Co-Diagnostics disclosed 23 risk factors in its most recent earnings report. Co-Diagnostics reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Co-Diagnostics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

CODX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
HSCSHSCS40Underperform$10.56M-0.66-816.25%―-27.70%61.44%
SINTSINT40Underperform$10.17M-0.60-309.86%―160.79%67.55%
VVOSVVOS40Underperform$3.29M-0.052616.82%―45.21%-10.29%
CODXCODX40Underperform$2.72M-0.01-322.92%―28.89%34.53%
ALURALUR39Underperform$2,0010.0044.17%―-55.49%21.55%
ADGMADGM37Underperform$1.77M-0.04-661.85%―-100.00%70.33%

* General Sector Average

Performance Comparison

-100%-50%0%50%100%CODXSINTVVOSADGMALURHSCSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CODX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CODXCo-Diagnostics0.26-9.23-97.28%
SINTSintx Technologies1.34-2.15-61.46%
VVOSVivos Therapeutics, Inc.0.10-2.29-95.90%
ADGMAdagio Medical Holdings, Inc1.93-21.17-91.65%
ALURAllurion Technologies, Inc.0.02-20.98-99.90%
HSCSHeart Test Laboratories, Inc.2.13-0.88-29.17%

Co-Diagnostics Corporate Events

Business Operations and StrategyShareholder Meetings

Co-Diagnostics Plans Special Meeting After Quorum Shortfalls

Negative
Oct 15, 2026

Co-Diagnostics, Inc. disclosed that it was unable to conduct business at its Annual Meeting of Stockholders originally held on September 3, 2026, because a quorum was not present or represented. The meeting was adjourned and reconvened on September 2...

Business Operations and StrategyPrivate Placements and Financing

Co-Diagnostics Secures Convertible Financing to Bolster Liquidity

Negative
Oct 13, 2026

On October 9, 2026, Co-Diagnostics entered into a senior secured convertible loan agreement with J.J. Astor & Co. for up to $3.1 million in funding, receiving $2.1 million at closing and the ability to draw an additional $1.0 million subject to condi...

Regulatory Filings and ComplianceShareholder Meetings

Co-Diagnostics Faces Repeated Annual Meeting Quorum Delays

Negative
Sep 25, 2026

Co-Diagnostics, Inc. reported that its Annual Meeting of Stockholders originally held on September 3, 2026, did not achieve a quorum, preventing any business from being conducted and prompting an adjournment to September 24, 2026. When the adjourned...

Business Operations and StrategyRegulatory Filings and Compliance

Co-Diagnostics Highlights PCR Platform and Global Partnerships

Positive
Sep 16, 2026

On September 16, 2026, Co-Diagnostics, Inc. plans to host an investor and analyst presentation highlighting its collaboration with ReadyGo Diagnostics Ltd., its Co-Dx PCR platform, and associated development and manufacturing initiatives, including i...

Business Operations and StrategyProduct-Related Announcements

Co-Diagnostics partners on blood-based PCR Ebola testing

Positive
Sep 16, 2026

On September 16, 2026, Co-Diagnostics and ReadyGo Diagnostics announced a collaboration to evaluate combining the Co-Dx PCR platform with ReadyGo’s GoCollect blood sample-preparation system for point-of-need molecular testing. The initial application...

Business Operations and StrategyProduct-Related Announcements

Co-Diagnostics Tests ReadyGo Tech for PCR Platform

Neutral
Sep 15, 2026

In August 2026, Co-Diagnostics entered into a material transfer agreement with ReadyGo Diagnostics to assess the compatibility of ReadyGo’s sample collection and preparation technologies with the Co-Dx PCR platform. ReadyGo’s materials are designed t...

Executive/Board Changes

Co-Diagnostics Appoints New Principal Financial Officer

Neutral
Sep 4, 2026

On September 2, 2026, Co-Diagnostics, Inc. announced that Chief Financial Officer Brian Brown’s employment ended on that date, concluding his tenure as principal financial and accounting officer. Effective the same day, Executive Vice President of Fi...

Regulatory Filings and ComplianceShareholder Meetings

Co-Diagnostics Adjourns Annual Meeting, Sets New Date

Negative
Sep 4, 2026

Co-Diagnostics, Inc. held its previously announced Annual Meeting of Stockholders on September 3, 2026, but the meeting failed to reach a quorum and therefore could not conduct any formal business. Under the company’s bylaws, the chairperson adjourne...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 11, 2026